SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
SELLAS Life Sciences Group (NASDAQ: SLS) has announced its upcoming presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, scheduled for May 30-June 3, 2025. The presentation will showcase preclinical efficacy data of SLS009 (tambiciclib) in ASXL1 mutated colorectal cancer.
The poster presentation, scheduled for June 2, 2025 (1:30 PM-4:30 PM CDT), will be displayed in Hall A under abstract #3121. The full abstract will be released on ASCO's website on May 22, 2025. Currently, SLS009 is undergoing a Phase 2 clinical trial evaluating its safety and efficacy in combination with venetoclax and azacitidine for AML patients with ASXL1 mutations.
SELLAS Life Sciences Group (NASDAQ: SLS) ha annunciato la sua prossima presentazione al 2025 American Society of Clinical Oncology (ASCO) Annual Meeting che si terrà a Chicago dal 30 maggio al 3 giugno 2025. La presentazione mostrerà i dati preclinici di efficacia di SLS009 (tambiciclib) nel cancro colorettale con mutazione ASXL1.
La presentazione poster, prevista per il 2 giugno 2025 (dalle 13:30 alle 16:30 CDT), sarà esposta nella Hall A con il numero di abstract #3121. Il testo completo dell’abstract sarà pubblicato sul sito ASCO il 22 maggio 2025. Attualmente, SLS009 è in fase di studio clinico di Fase 2 per valutarne la sicurezza e l’efficacia in combinazione con venetoclax e azacitidina nei pazienti con leucemia mieloide acuta (AML) portatori di mutazioni ASXL1.
SELLAS Life Sciences Group (NASDAQ: SLS) ha anunciado su próxima presentación en la Reunión Anual 2025 de la Sociedad Americana de Oncología Clínica (ASCO) en Chicago, programada del 30 de mayo al 3 de junio de 2025. La presentación mostrará datos preclínicos de eficacia de SLS009 (tambiciclib) en cáncer colorrectal con mutación ASXL1.
La presentación en formato póster, programada para el 2 de junio de 2025 (de 1:30 PM a 4:30 PM CDT), se exhibirá en el Salón A bajo el resumen #3121. El resumen completo se publicará en el sitio web de ASCO el 22 de mayo de 2025. Actualmente, SLS009 está en un ensayo clínico de Fase 2 que evalúa su seguridad y eficacia en combinación con venetoclax y azacitidina para pacientes con leucemia mieloide aguda (LMA) con mutaciones ASXL1.
SELLAS Life Sciences Group (NASDAQ: SLS)는 2025년 5월 30일부터 6월 3일까지 시카고에서 열리는 2025 미국임상종양학회(ASCO) 연례회의에서 발표할 예정임을 발표했습니다. 이번 발표에서는 ASXL1 변이가 있는 대장암에 대한 SLS009(탐비시클립)의 전임상 효능 데이터를 소개할 예정입니다.
포스터 발표는 2025년 6월 2일 오후 1시 30분부터 4시 30분(CDT)까지 A홀에서 초록 번호 #3121로 진행됩니다. 전체 초록은 2025년 5월 22일 ASCO 웹사이트에 공개될 예정입니다. 현재 SLS009는 ASXL1 변이가 있는 급성 골수성 백혈병(AML) 환자를 대상으로 베네토클락스와 아자시티딘과 병용한 2상 임상시험을 진행 중입니다.
SELLAS Life Sciences Group (NASDAQ : SLS) a annoncé sa prochaine présentation lors du Congrès annuel 2025 de l’American Society of Clinical Oncology (ASCO) à Chicago, prévu du 30 mai au 3 juin 2025. La présentation mettra en avant des données précliniques d’efficacité de SLS009 (tambiciclib) dans le cancer colorectal muté ASXL1.
La présentation sous forme de poster, prévue le 2 juin 2025 (de 13h30 à 16h30 CDT), sera exposée dans le hall A sous le numéro d’abstract #3121. L’abstract complet sera publié sur le site d’ASCO le 22 mai 2025. Actuellement, SLS009 est en essai clinique de phase 2 évaluant sa sécurité et son efficacité en association avec le venetoclax et l’azacitidine chez des patients atteints de leucémie myéloïde aiguë (LMA) avec mutations ASXL1.
SELLAS Life Sciences Group (NASDAQ: SLS) hat seine bevorstehende Präsentation auf dem Jahrestreffen 2025 der American Society of Clinical Oncology (ASCO) in Chicago angekündigt, das vom 30. Mai bis 3. Juni 2025 stattfindet. Die Präsentation wird präklinische Wirksamkeitsdaten von SLS009 (tambiciclib) bei ASXL1-mutiertem kolorektalem Krebs vorstellen.
Die Posterpräsentation ist für den 2. Juni 2025 (13:30–16:30 Uhr CDT) geplant und wird in Halle A unter dem Abstract #3121 gezeigt. Das vollständige Abstract wird am 22. Mai 2025 auf der ASCO-Website veröffentlicht. Derzeit befindet sich SLS009 in einer Phase-2-Studie, die Sicherheit und Wirksamkeit in Kombination mit Venetoclax und Azacitidin bei AML-Patienten mit ASXL1-Mutationen untersucht.
- None.
- None.
- ASCO Presentation to Highlight Preclinical Efficacy of SLS009 (tambiciclib) in ASXL1 Mutated Colorectal Cancer -
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical efficacy of SLS009 in ASXL1 mutated colorectal cancer lines will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30- June 3, 2025 in Chicago, Illinois.
Poster presentation details:
Title: In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines.
Session Date and Time: Monday, June 2, 2025, 1:30 PM-4:30 PM CDT
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Location: Hall A - Posters and Exhibits
Abstract #: 3121
Poster Board #: 436
The full text of the abstract will be released by ASCO on May 22, 2025, at 5:00 PM EDT on asco.org/abstracts.
SLS009 is currently being investigated in a Phase 2 open-label, single-arm, multi-center study designed to evaluate the safety, tolerability, and efficacy of SLS009 in combination with venetoclax and azacitidine including AML patients with ASXL1 mutations. Initial clinical safety and efficacy data are available. In addition, the study aims to identify biomarkers for the target patient population and enrichment for further trials. For more information on the study, visit clinicaltrial.gov identifier NCT04588922.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared to other CDK9 inhibitors. Data suggests that SLS009 demonstrated a high response rate in AML patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases. For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the GPS clinical development program, including the REGAL study and the timing of future milestones related thereto. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 20, 2025 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contact
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
FAQ
When will SELLAS present SLS009 data at ASCO 2025?
What is the current development stage of SLS009 (tambiciclib)?
What type of cancer is SLS009 being studied for in the ASCO 2025 presentation?
When will the full abstract of SELLAS's ASCO presentation be available?
What is the clinical trial identifier for the ongoing SLS009 study?
